Haldor Topsøe remains the largest shareholder of cancer treatment developer IGM Biosciences, whose shares have risen more than 50% since it floated yesterday.

US-based cancer therapy developer IGM Biosciences went public yesterday in a $175m initial public offering that scored an exit for catalyst producer Haldor Topsøe. The company priced more than 10.9 million shares on the Nasdaq Global Select Market at $16.00 each, in the middle of the IPO’s $15 to $17 range, giving it a market…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.